Novartis Share Price Today | Stock Price & Novartis Share Screener
As of November 2, 2026, the live Novartis share price (NSE: NOVARTIND) is ₹1,717.70 on NSE and ₹1,718.35 on BSE, up 1.49% from the previous close, with shares trading between ₹1,693.30 and ₹1,799.60 in today's trading session, and a 52-week range of ₹962.00–₹2,428.20. Track NOVARTIND market cap trends to gauge the company's total market size. Use the Novartis stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Novartis opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹408 and net income of ₹98, with EBITDA of ₹139, an operating margin of 27.0% and a profit margin of 24.0%.
Novartis Share Price Chart
Track the current stock price of Novartis with an interactive chart. Analyse NOVARTIND share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Novartis stock quote in one place.
The quote of ₹1,717.70 sits between the 52-week low of ₹962.00 and the 52-week high of ₹2,428.20, and the latest session moved 1.49% from the previous close.
Novartis Company Profile - Fundamental Screener
Screen Novartis company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for NOVARTIND shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE234A01025.
Company Details
Classification
Identifiers and Leadership
Novartis Balance Sheet Screener
Screen NOVARTIND balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹978, up from ₹948 in 2025.
Latest statistics put total assets at ₹978 and shareholder funds at ₹818, with a leverage ratio of 0.01.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 978 | 948 | 925 | 983 | 958 | 1,002 | 1,078 | 982 | 1,111 | 1,150 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 3 | 5 | 7 | 19 | 24 | 64 | 76 | 15 | 5 | 6 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 16 | 21 | 23 | 48 | 50 | 132 | 124 | 38 | 47 | 47 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 818 | 785 | 745 | 776 | 692 | 711 | 721 | 759 | 734 | 920 |
| Share Capital | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 14 |
| Reserves & Surplus | 806 | 773 | 733 | 763 | 679 | 699 | 708 | 747 | 721 | 906 |
Novartis Income Statement Screener - Profit & Revenue Analysis
Screen Novartis income statement and profit fundamentals. Analyze NOVARTIND quarterly results. Novartis reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹408 and net profit was ₹98, equal to earnings per unit of ₹39.60, at an operating margin of 27%.
In that period expenses were ₹269, interest cost ₹1 and tax ₹37. The next period listed, 2026-March, shows revenue of ₹393 and net profit of ₹93.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 408 | 393 | 398 | 397 | 437 | 433 | 414 | 474 | 569 | 736 | 727 | 771 | 981 |
| Expenses | 269 | 260 | 265 | 270 | 314 | 373 | 355 | 426 | 478 | 570 | 631 | 656 | 877 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 139 | 133 | 133 | 127 | 123 | 60 | 60 | 48 | 91 | 166 | 96 | 115 | 104 |
| Operating Profit % | 27.00% | 27.00% | 26.00% | 19.00% | 17.00% | 7.00% | 7.00% | 3.00% | 3.00% | -1.00% | 4.00% | 5.00% | 0.00% |
| Depreciation | 2 | 2 | 2 | 3 | 6 | 10 | 12 | 13 | 3 | 3 | 4 | 4 | 4 |
| Interest | 1 | 1 | 1 | 2 | 2 | 5 | 8 | 6 | 2 | 6 | 1 | 0 | 0 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 136 | 130 | 130 | 123 | 115 | -4 | 40 | 29 | 86 | 158 | 92 | 111 | 93 |
| Tax | 37 | 37 | 30 | 38 | 12 | 0 | 19 | 19 | 34 | 79 | 35 | 39 | 14 |
| Net Profit | 98 | 93 | 101 | 85 | 103 | -4 | 21 | 10 | 52 | 78 | 57 | 73 | 79 |
| EPS | 39.60 | 37.74 | 40.87 | 34.50 | 41.86 | -1.51 | 8.46 | 4.08 | 20.97 | 28.43 | 19.10 | 62.04 | 24.75 |
Novartis Cash Flow Screener - Liquidity Fundamentals
Screen NOVARTIND cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹47.
Over the same period, investing activities provided ₹18 and financing activities used ₹64.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 47 | 75 | 113 | 45 | 39 | -69 | -23 | -194 | 161 | -41 |
| Investing Activities | 18 | -3 | 33 | -153 | 87 | 95 | 56 | 274 | 69 | 424 |
Financing and Net Cash | ||||||||||
| Financing Activities | -64 | -64 | -121 | -31 | -36 | -37 | -41 | -30 | -268 | -332 |
| Net Cash Flow | 0 | 7 | 26 | -139 | 90 | -11 | -9 | 50 | -38 | 51 |
Novartis Shareholding Pattern Screener
See Novartis shareholding pattern with promoter, FII, and DII holdings. Check Novartis promoter holding and ownership changes for NOVARTIND on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 70.68%, foreign institutions 0.17%, domestic institutions 0.53% and the public 23.25%, spread across 38,116 shareholders.
The shareholder count was 38,116 in 2026-Mar, compared with 36,502 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Jul | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% |
Institutional Investors | ||||||||
| FII Holding | 0.17% | 0.16% | 0.15% | 1.22% | 0.19% | 0.19% | 0.19% | 0.19% |
| DII Holding | 0.53% | 1.36% | 1.39% | 1.50% | 0.53% | 0.53% | 0.53% | 0.64% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.25% | 22.50% | 22.43% | 21.29% | 23.11% | 22.95% | 22.92% | 22.67% |
| Other Holding | 5.36% | 5.31% | 5.35% | 5.31% | 5.49% | 5.66% | 5.68% | 5.83% |
| Shareholder Count | 38,116 | 36,502 | 36,706 | 38,127 | 39,133 | 39,040 | 39,353 | 39,468 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Novartis. Novartis dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹25.00 per unit for 2026-March, a yield of 1.48%, compared with ₹25.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹25.00, ₹25.00 and ₹25.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹25.00 | 1.48% |
| 2025-March | ₹25.00 | 2.58% |
| 2024-March | ₹25.00 | 3.18% |
| 2023-March | ₹47.50 | 7.07% |
| 2022-March | ₹10.00 | 1.77% |
| 2021-March | ₹10.00 | 1.70% |
| 2020-March | ₹10.00 | 1.81% |
| 2019-March | ₹10.00 | 1.99% |
| 2018-March | ₹10.00 | 1.46% |
| 2017-March | ₹10.00 | 1.63% |
Novartis Stock Index Membership - Nifty & Sensex
See which indices include Novartis stock. Check NOVARTIND index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 3 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP.
Complete Index List
Novartis Market Events Screener - Corporate Actions
Get Novartis corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Novartis stock events that may affect NOVARTIND share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 3, 2026, with a record date of November 3, 2026.
It is followed by Annual General Meeting dated September 24, 2026 and Quarterly Result Announcement dated July 23, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-03 | 2026-11-03 | Quarterly Result Announcement | NA | -11.97% |
| 2026-09-24 | 2026-09-24 | Annual General Meeting | NA | 26.59% |
| 2026-07-23 | 2026-07-23 | Quarterly Result Announcement | NA | 16.63% |
| 2026-05-12 | 2026-05-12 | Quarterly Result Announcement | NA | 21.81% |
| 2026-01-28 | 2026-01-28 | Quarterly Result Announcement | NA | 3.23% |
| 2025-10-28 | 2025-10-28 | Quarterly Result Announcement | NA | -3.77% |
| 2025-07-31 | 2025-07-31 | Annual General Meeting | NA | 24.87% |
| 2025-07-29 | 2025-07-29 | Quarterly Result Announcement | NA | -0.92% |
| 2025-07-23 | 2025-07-23 | Dividend | ₹ 25.00 /share | 33.11% |
| 2025-05-09 | 2025-05-09 | Quarterly Result Announcement | NA | -3.94% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -4.09% |
| 2024-10-25 | 2024-10-25 | Quarterly Result Announcement | NA | -9.21% |
| 2024-07-31 | 2024-07-31 | Annual General Meeting | NA | 11.66% |
| 2024-07-23 | 2024-07-24 | Dividend | ₹ 25.00 /share | 5.99% |
| 2023-07-20 | 2023-07-21 | Dividend | ₹ 10.00 /share | 32.63% |
Novartis Competitors Screener - Peer Stocks Comparison
Screen NOVARTIND competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 426,530 | 34.90 | 61,674 | 12.69% | 11,565 | 47.71 |
| Divis Laboratories | 259,628 | 87.60 | 11,067 | 13.95% | 2,568 | 64.36 |
| Torrent Pharmaceuticals | 175,479 | 82.70 | 13,886 | 20.34% | 2,138 | 44.74 |
| Laurus Labs | 129,972 | 111.30 | 6,868 | 22.01% | 890 | 78.71 |
| Zydus Life Science | 124,239 | 25.80 | 27,658 | 17.64% | 5,026 | 70.87 |
| Dr Reddys Laboratories | 112,849 | 40.50 | 35,059 | 3.90% | 4,158 | 75.33 |
| Cipla | 111,396 | 38.40 | 29,045 | 2.24% | 3,870 | 59.16 |
| Mankind Pharma | 102,964 | 44.90 | 14,636 | 14.85% | 1,938 | 58.49 |
| Aurobindo Pharma | 96,744 | 25.70 | 34,145 | 5.56% | 3,503 | 54.82 |
| Lupin | 91,961 | 16.50 | 29,039 | 26.75% | 5,356 | 51.38 |
Novartis Company Announcements - News & Reports Screener
Screen NOVARTIND latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 30, 2026.
The next most recent announcements are dated October 30, 2026 and October 14, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-30 | Intimation Of The Earnings Call Proposed To Be Held On November 04 2026 At 02:30 PM IST | - |
| 2026-10-30 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-10-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-10-13 | Notice Of Postal Ballot (02/2026-27) - Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) Of Evonile Pharma Limited (Formerly Known As Novar | - |
| 2026-10-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-08 | Announcement under Regulation 30 (LODR)-Raising of Funds | - |
| 2026-10-08 | Announcement under Regulation 30 (LODR)-Issue of Securities | - |
| 2026-10-08 | Board Meeting Outcome for Intimation Of The Outcome Of The Board Meeting Held Today Dated October 08 2026 | - |
| 2026-10-07 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-10-05 | Board Meeting Intimation for Consideration Of Raising Of Funds Through The Issuance Of Equity Shares Of The Company. | - |
| 2026-10-01 | Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association | - |
| 2026-10-01 | Announcement under Regulation 30 (LODR)-Change of Company Name | - |
| 2026-09-30 | Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026. | - |
| 2026-09-30 | Closure of Trading Window | - |
| 2026-09-25 | Intimation Of The Voting Results And The Scrutinizers Report For The 78Th Annual General Meeting Of The Company Held On Thursday September 24 2026. | - |
| 2026-09-24 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-23 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-09-21 | Intimation Regarding The Newspaper Publication Made Regarding The Corrigendum Filed Dated September 18 2026 For The Notice Of 78Th Annual General Meeting | - |
| 2026-09-18 | Corrigendum To The Notice Of 78Th Annual General Meeting | - |
| 2026-09-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,717.70, within a 52-week range of ₹962.00 to ₹2,428.20. The P/E ratio is 45.80 and the P/B ratio is 5.47, with earnings per unit of ₹37.74. Market capitalisation stands at ₹4,178.67 Cr and the dividend yield is 1.38%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 4, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.